Dr. Dichtel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit Street
Bul457, Neurendocrine Unit
Boston, MA 02114Phone+1 617-726-3870- Is this information wrong?
Education & Training
- Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2012 - 2015
- Brigham and Women's HospitalResidency, Internal Medicine, 2009 - 2012
- Yale School of MedicineClass of 2009
Certifications & Licensure
- MA State Medical License 2012 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease Start of enrollment: 2022 Aug 10
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Author Correction: Clonal haematopoiesis and risk of chronic liver disease.Waihay J Wong, Connor Emdin, Alexander G Bick, Seyedeh M Zekavat, Abhishek Niroula, James P Pirruccello, Laura Dichtel, Gabriel Griffin, Md Mesbah Uddin, Christopher J...> ;Nature. 2023 Jul 1
- 4 citationsGrowth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial.Laura E Dichtel, Kathleen E Corey, Melanie S Haines, Mark L Chicote, Hang Lee, Allison Kimball, Caitlin Colling, Tracey G Simon, Michelle T Long, Jad Husseini, Miriam ...> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Nov 17
- 37 citationsClonal haematopoiesis and risk of chronic liver disease.Waihay J Wong, Connor Emdin, Alexander G Bick, Seyedeh M Zekavat, Abhishek Niroula, James P Pirruccello, Laura Dichtel, Gabriel Griffin, Md Mesbah Uddin, Christopher J...> ;Nature. 2023 Apr 1
- Join now to see all
Press Mentions
- Top in Endocrinology: Nonalcoholic Fatty Liver Disease in Patients with Obesity, DiabetesJune 29th, 2022
- Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call TranscriptMay 11th, 2022
- Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialMay 5th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: